Breathing-Maneuver-Induced Myocardial Oxygenation Reserve Validated by FFR (B-MORE)
Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Oct 11, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The B-MORE trial is studying a new way to help doctors understand how well the heart is getting enough oxygen in patients who may have a condition called coronary artery stenosis, which means their heart arteries are narrowed. The goal is to find a reliable marker that shows how well the heart is responding to oxygen needs. The trial is currently looking for participants aged 18 and older, whether they are healthy or have coronary artery disease, as long as they don't have certain medical conditions that could interfere with the study.
If you join this trial, you'll undergo some tests to check your heart's oxygen levels. It's important to note that there are some restrictions: you shouldn't have any heart devices like pacemakers or be pregnant, and you must avoid caffeine and nicotine before the exam. This study aims to provide better tools for diagnosing heart issues, which could ultimately help improve treatment options for patients with heart problems.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy Participants
- • Age: \> 40y
- • No known current or pre-existing significant medical problems that would affect the cardiovascular or respiratory system.
- • CAD Patients
- • Age \> 18 y
- • Indication for invasive coronary angiography based on symptoms and a test positive for inducible coronary ischemia, or previous coronary angiography.
- Exclusion Criteria:
- ALL participants:
- • General MRI contraindications: Pacemakers, defibrillating wires, implanted defibrillators, intracranial aneurysm clips, metallic foreign bodies in the eyes, knowledge or suspicion of pregnancy.
- • Consumption of caffeine (coffee, tea, cocoa, chocolate, "energy drink") during the 12 hours prior to the exam.
- • Regular nicotine consumption during the last 6 months.
- • Patients only
- • Vasoactive medication (e.g. nitro) during the 12 hours prior to the exam Contraindications to adenosine (2nd or 3rd A-V block, sinus node disease, asthma, bronchoconstrictive diseases).
- • Acute Coronary Syndrome (ACS), or previous Coronary Artery Bypass Surgery
- • Previous myocardial infarction within 1 month
- • Clinically unstable condition
- • Significant or uncontrolled arrhythmia
About Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre
The McGill University Health Centre (MUHC) and the Research Institute of the McGill University Health Centre (RI-MUHC) are leading institutions in clinical research and healthcare innovation. With a commitment to advancing medical knowledge and improving patient outcomes, the MUHC integrates cutting-edge research with high-quality patient care. The RI-MUHC fosters a collaborative environment where multidisciplinary teams engage in transformative research across various fields, including oncology, neurology, and cardiovascular health. By leveraging state-of-the-art facilities and a robust network of clinical expertise, both entities strive to translate scientific discoveries into effective treatments, ultimately enhancing the quality of life for patients locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Matthias G Friedrich, MD
Principal Investigator
Reseach Institute of the McGill University health Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials